Atossa Therapeutics (ATOS) Net Shares Issued and Repurchased (2022 - 2026)

Atossa Therapeutics (ATOS) has reported Net Shares Issued and Repurchased for 5 consecutive years, with $90535.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Net Shares Issued and Repurchased fell 32.74% year-over-year to $90535.0 in Q1 2026; TTM through Mar 2026 was $90535.0, a 32.74% decrease from a year earlier, with the FY2025 full-year figure at $344548.0, down 92.67% from the prior year.
• Net Shares Issued and Repurchased was $90535.0 for Q1 2026 at Atossa Therapeutics, down from $344548.0 in the prior quarter.
• Over five years, Net Shares Issued and Repurchased peaked at $6.8 million in Q4 2023 and troughed at $90535.0 in Q1 2026.
• A 5-year average of $2.6 million and a median of $2.5 million in 2023 frame the typical range for Net Shares Issued and Repurchased.
• Across the five-year window, Net Shares Issued and Repurchased soared 67.38% in 2023 and plunged 92.67% in 2025, its largest moves.
• Over 5 years, Net Shares Issued and Repurchased stood at $4.1 million in 2022, then soared by 67.38% to $6.8 million in 2023, then tumbled by 31.15% to $4.7 million in 2024, then sank by 92.67% to $344548.0 in 2025, then slumped by 73.72% to $90535.0 in 2026.
• The last three Net Shares Issued and Repurchased figures came in at $90535.0 (Q1 2026), $344548.0 (Q4 2025), and $4.2 million (Q2 2025), per Business Quant data.